Abstract | AIMS: METHODS: A phase IIIb, open-label, 1:1 randomized, active-controlled, 24-week multicentre study of T2DM patients inadequately controlled on metformin was conducted. Patients were administered lixisenatide before breakfast or the main meal. The primary endpoint was change from baseline at week 24 in glycated haemoglobin (HbA1c). Other endpoints: changes in body weight, fasting plasma glucose (FPG), 7-point self-monitored plasma glucose (SMPG) and Diabetes Treatment Satisfaction Questionnaire status (DTSQs) score. Adverse events (AEs) were monitored. RESULTS: Mean change in HbA1c from baseline at week 24 was -0.65% (-7.1mmol/mol; main meal) and -0.74% (-8.1mmol/mol; breakfast). Mean changes in FPG, body weight and DTSQs score were comparable between groups. The mean change in body weight (kg) was -2.60 (main meal) and -2.80 (breakfast group). The 7-point SMPG profiles showed greatest reductions in postprandial glucose after the meal at which lixisenatide was administered, with a residual effect seen on the subsequent meal. AE rates were similar between groups, including gastrointestinal AEs. CONCLUSIONS:
|
Authors | Bo Ahrén, Natalia Vorokhobina, Elisabeth Souhami, Nacima Demil, Jenny Ye, Ronnie Aronson |
Journal | Journal of diabetes and its complications
(J Diabetes Complications)
2014 Sep-Oct
Vol. 28
Issue 5
Pg. 735-41
ISSN: 1873-460X [Electronic] United States |
PMID | 25012990
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Peptides
- hemoglobin A1c protein, human
- lixisenatide
|
Topics |
- Aged
- Blood Glucose
(drug effects, metabolism)
- Breakfast
(drug effects)
- Drug Administration Schedule
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Hypoglycemic Agents
(administration & dosage, adverse effects)
- Male
- Meals
(drug effects)
- Middle Aged
- Peptides
(administration & dosage, adverse effects)
- Postprandial Period
(drug effects)
- Time Factors
- Treatment Outcome
|